Form 4: Oruka Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Lawrence Otto Klein, Chief Executive Officer and a Director of Oruka Therapeutics, Inc., sold 75,000 shares of common stock on September 1, 2026.
Summary
- Option exercise/conversion: acquired 75,000 Common Stock at $7.80 ($585,000) on September 1, 2026; holds 1,000,580 after (Direct).
- Open-market sale: disposed of 6,604 Common Stock at $90.79 ($599,556) on September 1, 2026; holds 993,976 after (Direct).
- Open-market sale: disposed of 63,596 Common Stock at $91.90 ($5,844,237) on September 1, 2026; holds 930,380 after (Direct).
- Open-market sale: disposed of 4,800 Common Stock at $92.44 ($443,691) on September 1, 2026; holds 925,580 after (Direct).
- Option exercise/conversion: disposed of 75,000 Employee Warrant (right to buy) on September 1, 2026; holds 1,553,513 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $6,887,484 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Lawrence Otto Klein — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Option exercise/conversion | Common Stock | 75,000 | $8 | $585.0K | 1,000,580 |
| 2026-09-01 | Open-market sale | Common Stock | 6,604 | $91 | $599.6K | 993,976 |
| 2026-09-01 | Open-market sale | Common Stock | 63,596 | $92 | $5.8M | 930,380 |
| 2026-09-01 | Open-market sale | Common Stock | 4,800 | $92 | $443.7K | 925,580 |
| 2026-09-01 | Option exercise/conversion | Employee Warrant (right to buy) | 75,000 | — | — | 1,553,513 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Option exercise/conversion (75,000 shares) |
| 2026-09-01 | Open-market sale (6,604 shares) |
| 2026-09-01 | Open-market sale (63,596 shares) |
| 2026-09-01 | Open-market sale (4,800 shares) |
| 2026-09-01 | Option exercise/conversion (75,000 shares) |
Keywords
insider transaction, Form 4, ORKA, Oruka Therapeutics, Inc., bearish, Lawrence Otto Klein
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.